Insider Selling: Privia Health Group (NASDAQ:PRVA) CFO Sells $141,278.80 in Stock

Privia Health Group, Inc. (NASDAQ:PRVA) CFO David Mountcastle sold 6,565 shares of the firm’s stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $21.52, for a total transaction of $141,278.80. Following the completion of the transaction, the chief financial officer directly owned 226,804 shares of the company’s stock, valued at $4,880,822.08. This represents a 2.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

David Mountcastle also recently made the following trade(s):

• On Monday, March 16th, David Mountcastle sold 6,391 shares of Privia Health Group stock. The stock was sold at an average price of $22.11, for a total value of $141,305.01.
• On Thursday, March 12th, David Mountcastle sold 6,453 shares of Privia Health Group stock. The shares were sold at an average price of $21.90, for a total value of $141,320.70.
• On Monday, March 9th, David Mountcastle sold 5,829 shares of Privia Health Group stock. The shares were sold at an average price of $22.84, for a total value of $133,134.36.
• On Friday, March 6th, David Mountcastle sold 5,177 shares of Privia Health Group stock. The stock was sold at an average price of $23.15, for a total value of $119,847.55.
• On Thursday, February 26th, David Mountcastle sold 5,361 shares of Privia Health Group stock. The stock was sold at an average price of $25.00, for a total value of $134,025.00.
• On Friday, February 27th, David Mountcastle sold 7,697 shares of Privia Health Group stock. The stock was sold at an average price of $25.05, for a total value of $192,809.85.

Privia Health Group Price Performance

PRVA stock opened at $21.59 on Thursday. The business’s 50-day moving average is $22.75 and its two-hundred day moving average is $23.60. The firm has a market capitalization of $2.67 billion, a P/E ratio of 127.00, a P/E/G ratio of 1.39 and a beta of 0.82. Privia Health Group, Inc. has a 1 year low of $18.77 and a 1 year high of $26.51.

Privia Health Group (NASDAQ:PRVA) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.21. Privia Health Group had a return on equity of 3.06% and a net margin of 1.08%.The business had revenue of $541.17 million during the quarter, compared to the consensus estimate of $516.61 million. During the same period in the previous year, the company posted $0.21 earnings per share. The business’s revenue for the quarter was up 17.4% on a year-over-year basis. On average, analysts expect that Privia Health Group, Inc. will post 0.14 EPS for the current year.

Hedge Funds Weigh In On Privia Health Group

Hedge funds have recently added to or reduced their stakes in the stock. Bayban purchased a new stake in Privia Health Group in the fourth quarter valued at approximately $26,000. Hantz Financial Services Inc. grew its position in shares of Privia Health Group by 456.2% during the fourth quarter. Hantz Financial Services Inc. now owns 1,129 shares of the company’s stock worth $27,000 after acquiring an additional 926 shares during the last quarter. Global Retirement Partners LLC grew its position in shares of Privia Health Group by 579.8% during the fourth quarter. Global Retirement Partners LLC now owns 1,584 shares of the company’s stock worth $38,000 after acquiring an additional 1,351 shares during the last quarter. Canada Pension Plan Investment Board increased its holdings in shares of Privia Health Group by 48.0% in the 2nd quarter. Canada Pension Plan Investment Board now owns 3,700 shares of the company’s stock valued at $85,000 after acquiring an additional 1,200 shares during the period. Finally, Kestra Advisory Services LLC acquired a new position in shares of Privia Health Group in the 4th quarter valued at $93,000. 94.48% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

PRVA has been the subject of several analyst reports. Citigroup lowered their price target on shares of Privia Health Group from $34.00 to $32.00 and set a “buy” rating for the company in a report on Tuesday, March 3rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Privia Health Group in a research report on Monday, December 29th. Wolfe Research set a $31.00 target price on shares of Privia Health Group in a research note on Tuesday, January 6th. Royal Bank Of Canada assumed coverage on Privia Health Group in a report on Friday, January 9th. They issued an “outperform” rating and a $31.00 target price on the stock. Finally, Canaccord Genuity Group raised their price target on Privia Health Group from $34.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Thirteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $31.00.

About Privia Health Group

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.